2024 Digital Health New Quality Productivity Innovation Case Selection Results Announced

Case Name:Personalized Brain Function Modulation for Diagnosis and Treatment

Selected Institutions:Beijing Galaxy Fangyuan Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Treatment of Brain Diseases

Annual Innovation Achievements and Outcomes:

Due to limited understanding of human brain functional networks and disease-related neural circuits, effective treatments for brain disorders are generally lacking. The personalized Brain Functional Segmentation (pBFS) technology can precisely parcellate the brain of each individual into 213 well-defined functional regions with clear boundaries, helping doctors and scientists elucidate the functional circuit mechanisms underlying brain disorders, thereby improving the efficacy of their treatment.

Galaxy Fangyuan Group’s personalized brain function modulation diagnosis and treatment protocol is grounded in the fundamental mechanisms of the brain. Leveraging pBFS technology, it investigates functional circuits associated with brain disorders to formulate individualized brain circuit modulation plans for patients. By employing safe, non-invasive physical intervention methods for brain circuit modulation, the protocol aims to ameliorate brain disorders. Through clinical trials and applications conducted in collaboration with dozens of renowned hospitals across China, the personalized brain function modulation diagnosis and treatment protocol has demonstrated favorable outcomes. It currently covers 16 types of brain disorders, including autism spectrum disorder (autism), Parkinson’s disease, post-stroke aphasia/hemiplegia, and depression/anxiety disorders, spanning the departments of neurology, rehabilitation medicine, psychiatry, and pediatrics. This approach provides precise, safe, and personalized treatment solutions for hundreds of millions of brain disorder patients worldwide. Over the past three years, nearly 2,000 patients have been treated, with an overall effective rate exceeding 60%.

This treatment regimen offers three key advantages: first, its breakthrough efficacy, demonstrating significant results in numerous brain disorders that lack effective therapeutic options; second, its non-invasive safety profile, which allows for broader patient applicability with minimal side effects; and third, its individualized precision, achieving truly targeted therapy through personalized treatment plans.

Case Name:Alambel Corporate Executive Digital Health Management Service

Selected Institutions:Chengdu Gaoxin Xiangnanli Alanbell Clinic Co., Ltd.

Application Subfields/Departments/Disease Types:Medical Services, Digital Health, Health Management

Annual Innovation Achievements and Results:

Experts at the Alanbell Medical Department have established a relatively unique and effective system for disease prevention and scientific anti-aging through extensive literature review and research, advocating a three-step progressive health coaching concept known as the “3B” philosophy. The three Bs stand for Basic, Better, and Best.

During the management period, a five-in-one health management team is assigned to each executive. Leveraging the digital mall and Enterprise WeChat as the primary communication channels, the team provides N-to-1 comprehensive, accompanied management services. This enables executives to monitor changes in their health metrics anytime and anywhere, and to promptly adjust their health status through online consultations and management.

Leveraging AI algorithms and Alanbell Labs’ global patented specialized testing technology, we adopt a telemedicine service model to deliver fully online services—including testing, result retrieval, report interpretation, and intervention guidance. Our aim is to achieve precise health management with broader coverage, lower costs, and higher efficiency, targeting customers across China and even globally.

Case Name:Application and Effectiveness Analysis of the AI-Enabled, Companion-Based “Three-Physician Co-Management” Lifestyle Intervention Model in Obesity Prevention and Control

Selected Institutions:Guangzhou Nanda Fit Medical Health Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Chronic Disease Management and Weight Loss

Annual Innovation Achievements and Results:

Nanda Feite, a pioneer in the fields of medical weight management and diabetes management in China, is dedicated to leveraging cutting-edge medical artificial intelligence and new quality productive forces to build a leading digital healthcare platform for chronic disease management in the country. The company adopts an AI-enhanced, companionship-based "Three-Provider Co-Management" model. By integrating its self-developed AI agent, "Tangdou," from the user-facing application to the management backend, it enables automated workflows to deliver standardized and highly efficient lifestyle intervention services for patients with overweight/obesity and related complications. This model not only facilitates the large-scale, high-quality provision of chronic disease management services but also effectively reduces costs, thereby achieving inclusive and accessible care.

The company has cumulatively helped over 30,000 patients successfully lose weight and reduce body fat, maintain stable blood glucose levels, and significantly improve chronic disease indicators, demonstrating through practical case studies its remarkable efficacy in weight management and enhancing patient health outcomes. Nanjing FitTech has established collaborative partnerships with more than 40 Grade-A tertiary hospitals in Guangdong Province, Jiangsu Province, and Shanghai, as well as with institutions such as JD Health and Meinian Onehealth, in areas including obesity management models, service implementation, and technical support. These collaborations enable the provision of personalized lifestyle intervention plans, supporting products, and online follow-up services for patients at home.

Furthermore, Nanda Fit organizes nearly 100 free clinic sessions, 20 large-scale academic symposia, and close to 100 patient education programs and live-streamed classes annually, dedicated to improving awareness and treatment rates for obesity and diabetes. Leveraging its outstanding achievements, the company has been consecutively named one of the Top 50 Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area, recognized twice as a High-Tech Enterprise, honored as one of the Top 20 AIGC Healthcare Companies in the China Innovation and Entrepreneurship Competition in 2023, and selected as an exemplary case for weight management by the National Center for Chronic and Noncommunicable Disease Control and Prevention of the Chinese Center for Disease Control and Prevention in 2024, fully demonstrating its professional expertise and innovative capabilities in the field of chronic disease management.

Case Name:Construction of a Myopia Prevention and Control System Based on Ocular Biometric Big Data

Selected Institutions:Hainan Eye Hospital

Partner Organizations:12mm Health Technology (Hainan) Co., Ltd.

Application Subfields/Departments/Diseases:Myopia Prevention and Control in Adolescents

Annual Innovation Achievements and Results:

Hainan Eye Hospital, in collaboration with Twelve Millimeters Health Technology (Hainan) Co., Ltd., achieved significant progress and innovative outcomes in 2024 with their jointly developed “Myopia Prevention and Control System Based on Ocular Biometric Big Data.” Centered on innovative digital therapeutics, this system breaks through the limitations of traditional myopia prevention and control methods. By collecting data on children’s eye-use behaviors and environmental factors via smart wearable devices, and integrating these with the hospital’s Electronic Medical Record (EMR) and Picture Archiving and Communication System (PACS), the system enables digitalized and personalized myopia prevention and management.This product marks the first application of digital therapeutics in the field of myopia prevention and control, establishing a closed-loop digital diagnosis and treatment system that encompasses monitoring, analysis, and intervention. It facilitates a paradigm shift in myopia management from merely controlling progression to preventing onset. By leveraging artificial intelligence to assist physicians with analysis and decision-making, the system significantly enhances operational efficiency. Furthermore, through Internet of Things (IoT) technology, it enables the decentralization of high-quality medical services to primary care settings, thereby building a specialized medical consortium for myopia prevention and control.

As of March 27, 2024, this myopia risk factor monitor received its regulatory classification determination, becoming the first medical-grade product of its kind both domestically and internationally. The EMR (Electronic Medical Record) and PACS (Picture Archiving and Communication System) established in hospital optometry and refractive surgery departments were put into clinical use on June 11, 2024, serving over 100 outpatients daily. Related products are currently applying for a series of patents and software copyrights, some of which have already been approved. The implementation of this case has not only improved the efficiency and quality of medical services but also provided a novel solution for myopia prevention and control among adolescents, demonstrating significant social value and market potential.

Case Name:Intelligent Clinical Research and Digital Therapeutics Translation Platform (Slan-Bot)^®)

Selected Institutions:Hangzhou Zhilan Health Co., Ltd.

Application Subfields/Departments/Diseases:Clinical research, such as investigator-initiated trials (IITs), real-world studies (RWS), and patient follow-ups, along with the rapid translation of research achievements like digital therapeutics.

Annual Innovation Achievements and Outcomes:

Intelligent Clinical Research and Digital Therapeutics Translation Platform (Slan-Bot)^®) is a patient-centric, data- and AI-driven platform for medical research and digital therapeutics translation, independently developed by Zhilan Health. It serves as the foundational support for cultivating new quality productive forces in digital healthcare, accelerates the establishment of digital health concept validation centers, and builds a critical bridge for transforming scientific achievements from the laboratory through pilot-scale testing to commercialization. The platform innovatively integrates intelligent research with digital interventions. Leveraging extensive corpora and disease models, it supports the rapid assembly of intervention modules via low-code development to construct digital disease intervention solutions, thereby facilitating the seamless connection between medical research and proactive digital therapeutics products.

Slan-Bot^®The platform has served as the official underlying technological foundation for clinical research and digital health proof-of-concept initiatives in Southwest, East, and South China. It supports disease screening, cohort studies, regional diseases, occupational diseases, and common chronic conditions through various disease research and digital intervention services. Additionally, it collaborates with multiple Grade A tertiary hospitals on hospital-wide digital intelligence research and the translational implementation of digital therapeutics.

Case Name:"High-Quality Hospital Development: 'Data-Driven Proactive Whole-Hospital Blood Glucose Management Practices'"

Selected Institutions:Sinocare Inc. (300298)

Application Subfields/Departments/Disease Types:Chronic Disease Management, Endocrinology Department

Annual Innovation Achievements and Outcomes:

To enhance the management of diabetic patients in hospitals, Sinocare has established an endocrinology-led proactive diabetes consultation system. This system incorporates advanced hardware such as continuous glucose monitoring (CGM) systems and smart blood glucose meters, along with integrated modules for CGM, blood glucose monitoring (BGM), insulin pumps, and patient education. The system seamlessly interfaces with hospital information systems, including HIS, LIS, and EMR. It automatically identifies patients with abnormal blood glucose levels through intelligent screening mechanisms and notifies the attending physicians. By ensuring comprehensive acquisition and real-time updates of patient data, a professional endocrinology team provides unified management and close monitoring. Furthermore, via the DPM platform, the system delivers comprehensive health management services covering the entire course of diabetes care, both in-hospital and out-of-hospital, including but not limited to diabetes remission.

The system’s innovations include integrated hardware-software synergy, an intelligent screening and automated notification system, and the concept of virtual ward management. Its prominent advantages encompass comprehensive data integration capabilities, efficient healthcare collaboration mechanisms, and enhanced patient engagement. This system has improved blood glucose target attainment and management rates, reduced the average length of hospital stay, elevated hospital service quality, and fostered mutual benefits for other departments, such as non-endocrinology units. Addressing the high prevalence of hyperglycemia among hospitalized patients and the inefficiency of in-hospital consultations, the system leverages informatization and intelligence to implement endocrinology-led, hospital-wide blood glucose management, thereby improving medical quality and reducing doctor-patient disputes.

Case Name:Construction of Next-Generation Intelligent Specialty Centers for Parkinson’s Disease

Selected Institutions:Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Collaborating Organizations:Shenzhen Zhenluo Technology Co., Ltd.

Application Subfields/Departments/Diseases:Neuroscience, Parkinson's Disease

Annual Innovation Achievements and Outcomes:

In April 2020, China’s first one-stop diagnosis and treatment center for Parkinson’s disease was established at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Ruijin Hospital and Zhenluo Science jointly created a model and application demonstration for the “New Generation Intelligent Specialty Center for Parkinson’s Disease.” By integrating classic diagnostic and therapeutic techniques with cutting-edge artificial intelligence and digital technologies, the “New Generation Intelligent Specialty Center for Parkinson’s Disease” has implemented intelligent clinical workflows—including in-hospital pre-consultation, laboratory and imaging tests, intelligent symptom assessment, and visualized consultations—as well as intelligent management models featuring continuous out-of-hospital quantitative monitoring, regular quantitative evaluations, effective doctor-patient interaction, and dynamic optimization of treatment efficacy. This initiative marks the world’s first implementation of a comprehensive spatiotemporal diagnosis and treatment system and model for Parkinson’s disease, truly realizing a broad-sense one-stop service covering “all timepoints, all settings, and the entire disease course,” namely the “New Generation Intelligent Specialty Center for Parkinson’s Disease.” Leveraging this application demonstration and related innovative technologies, the team from Ruijin Hospital and Zhenluo Science has published a series of high-quality papers (including multiple articles in top-tier journals) in internationally influential magazines, generating robust clinical evidence. Furthermore, they have collaborated with several leading hospitals across China to conduct prospective multicenter clinical studies. Currently, these concepts have been adopted by more than 90% of specialized Parkinson’s disease centers in China.

Case Name:Lianxin Smart Operating Room Integrated Solution

Selected Institutions:Shenzhen Lianxin Mobile Healthcare Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Smart Operating Room

Annual Innovation Achievements and Outcomes:

Lianxin’s Integrated Smart Operating Room Solution is a modern smart operating room system centered on surgical procedures, aimed at improving surgical quality and enhancing operational efficiency, while covering the entire perioperative process. The solution comprises one platform, four major product lines, over 40 intelligent terminal hardware devices, and 15 software systems. It focuses on the clinical workflows of the perioperative period, enabling refined management of all aspects involved, including personnel, supplies, equipment, work processes, and environment. By controlling surgical procedures, standardizing perioperative medical practices, ensuring surgical safety, and reducing surgical risks, the solution promotes standardized surgical operations through enhanced visualization and operational precision, ultimately delivering better clinical outcomes for patients.

Based on medical IoT technology, with the surgical procedure as the timeline and patient medical data at its core, this solution integrates the entire surgical workflow. It organically incorporates smart ward systems to achieve unified process management across preoperative, intraoperative, and postoperative stages. By providing comprehensive digital recording and centralized archiving of surgical procedures, it supplies data for clinical case studies, reduces medical errors, and thereby enhances operating room efficiency and the quality of medical services.

Case Name:WeDoctor Hainan Dongfang Digital Therapeutics Innovation Project

Selected Institutions:WeDoctor Group

Application Subfields/Departments/Diseases:Chronic Disease Health Management

Annual Innovation Performance and Achievements:

WeDoctor’s Hainan Dongfang Digital Therapeutics Innovation Project has broken down information barriers by establishing an interconnected smart platform, setting up chronic disease management centers and standardized chronic disease management clinics, driving process reengineering through digitalization, and creating standardized care pathways that integrate medical treatment with prevention. Additionally, the project has formed a hybrid “online + offline” team of health managers to upgrade the “3+1+N” grid-based service model. As of July 2024, the chronic disease management centers operating at Dongfang People’s Hospital and Gancheng Town Central Health Center had cumulatively managed 6,068 patients with hypertension and diabetes, completed 1,751 management plans, and conducted complication screening for 1,126 individuals. This initiative has addressed the shortage of non-clinical support staff in primary healthcare institutions and improved patient satisfaction. Through the joint efforts of health managers and medical teams, key management outcome indicators have shown significant improvement, yielding favorable management results.

Case Name:Integrated Data Governance Middle Platform Project of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Selected Institutions:Yidu Tech (2158.HK)

Collaborating Organizations:Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Application Subfields/Departments/Diseases:Smart Hospital

Annual Innovation Performance and Achievements:

The Integrated Data Governance Middle Platform Project at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is a key initiative driven by policy mandates and oriented toward digital transformation. It aims to comprehensively enhance the hospital’s informatization, lean management, and smart hospital development. The core objective is to establish a high-quality data asset system by instituting data governance organizations and regulations, developing a data standard framework, implementing data quality control, optimizing data collection and processing workflows, and continuously improving specific data governance goals. The construction of this platform marks a significant milestone in the hospital’s digital transformation. Leveraging cutting-edge technologies such as big data and artificial intelligence, Yidu Tech has helped build a hospital-wide data middle platform that covers all domains of hospital data. This platform achieves unified data collection, governance, management, and services for both historical and incremental data across clinical care, medical management, and operational management domains. By standardizing and structuring data, it creates a reusable and computable standardized data layer, and establishes a data asset platform, a research data platform, an operational metrics middle platform, and a data open platform. Medical staff, the Information Department, and third-party vendors can self-service perform data queries, dataset construction, data invocation, visual analysis and mining, and data reporting on the platform, thereby improving data usage efficiency and ensuring security and compliance, ultimately promoting the hospital’s digital transformation.

Case Name:Construction of a Demonstration System for Standardized Liver Disease Data Centers

Selected Organizations:Zhejiang Huzhou Huazhuo Information Technology Co., Ltd.

Collaborating Institutions:Shulan (Hangzhou) Hospital Co., Ltd.

Application Subfields/Departments/Disease Types:Diagnosis and Treatment of Liver Diseases, Scientific Research, and Public Health

Annual Innovation Achievements and Results:

The Standardized Liver Disease Data Center, jointly established by Huazhuo Technology and Shulan (Hangzhou) Hospital, is primarily applied in the fields of liver disease diagnosis and treatment, scientific research, and public health. By establishing a scientific liver disease prediction system, data aggregation, standardized processing, and a comprehensive, multi-dimensional platform for collaborative research, it provides high-quality data support to medical institutions, research organizations, and public health departments. This enables more precise and personalized treatment plans for patients and promotes the digitalization and intelligent transformation of liver disease healthcare services. Its core construction focuses on unified data modeling, collection, governance, development, management, and service, thereby facilitating the circulation and application of liver disease medical data elements.

The Standardized Liver Disease Data Center leverages data model-based prediction, diagnosis, and treatment, integrating evidence-based medicine with advanced technologies to provide an evidence-based foundation for the management of liver diseases. This approach significantly enhances the standards of diagnosis, treatment, and monitoring, thereby reducing rates of missed and misdiagnoses. Through intelligent management, the center enables comprehensive tracking and management of patients throughout the entire course of their disease, ultimately improving therapeutic outcomes and quality of life. To date, the Standardized Liver Disease Data Center has managed nearly 60,000 liver disease cases, with hepatitis B virus (HBV) infections accounting for approximately one-sixth of the total. This has effectively reduced the risk of progression to liver cirrhosis and hepatocellular carcinoma, while conserving medical resources and lowering healthcare costs. Furthermore, in addition to providing systematic tools, the center empowers partner institutions through multidimensional support, including inviting top-tier expert teams to assist with personnel training, advanced studies, ward rounds, and consultations, thereby enhancing clinical capabilities and research proficiency. Currently, the center’s initiatives have helped Zhengzhou Third People’s Hospital achieve an average case closure rate of over 80%, and Shulan (Hangzhou) Hospital achieve a follow-up rate of over 90%.

Case Name:Application of Digital Accelerated Recovery Products in the Perioperative Period for Early-Stage Lung Cancer

Selected Organizations:Zhongxi Medical Technology (Wuxi) Co., Ltd.

Collaborating Organizations:The First Affiliated Hospital of Zhejiang University

Application by Sub-sector/Department/Disease Type:Thoracic Surgery

Annual Innovation Achievements and Results:

Current routine postoperative management for patients with early-stage lung cancer lacks effective interventions. Although enhanced recovery protocols are beneficial, they increase clinical workload and are insufficient in terms of intervention and rehabilitation guidance. Therefore, developing an effective remote intervention management model holds clinical significance.

Zhongxi Digital Therapeutics integrates multidisciplinary expert knowledge with patient data to develop deep learning models, thereby generating personalized management plans. Its value lies in enhancing the effectiveness and efficiency of out-of-hospital management, freeing up clinical resources, and improving the quality and standardization of therapeutic management. In prospective clinical studies, the post-discharge management outcomes achieved by Zhongxi’s solution were non-inferior to those of manual multidisciplinary management. These groundbreaking findings were presented at the 2024 World Conference on Lung Cancer.

This product can also be integrated with medical-grade home monitoring devices, enabling interconnectivity and in-depth analysis through IoT data to accelerate patient pulmonary function recovery, reduce postoperative complications, and support effective and timely post-discharge interventions. It not only meets the needs of leading hospitals but also provides best-in-class practices that exceed current capabilities for prefecture-level and county-level hospitals, thereby enhancing their diagnostic and treatment capacities. Currently, this product has been deployed to empower the construction of a digital ERAS (Enhanced Recovery After Surgery) management model within Zhejiang Province’s Major Disease Diagnosis and Treatment Platform, extending its influence to multiple ERAS demonstration centers across the province.

Case Name:Machine Learning-Based Digital Rehabilitation Therapy for Autism

Selected Institutions:Beijing Asou Aba Technology Co., Ltd.

Application Subfields/Departments/Diseases:Digital Therapeutics, Department of Pediatric Rehabilitation, Department of Child Health Care, Department of Developmental and Behavioral Pediatrics, Autism Spectrum Disorder, Developmental Delay

Annual Innovation Achievements and Results:

The machine learning-based digital therapeutic for autism spectrum disorder (ASD) has had its safety and efficacy empirically validated by an expert team from the Child Mental Health Center of Peking University Sixth Hospital. As the first ASD digital therapeutic product in China to achieve large-scale commercial sales, it generated over RMB 10 million in revenue during its first quarter on the market. Since July 2023, it has provided daily supplemental home-based digital rehabilitation services of a specified duration to children undergoing training at the Hainan Provincial Women and Children’s Medical Center Rehabilitation Center. The attrition rate after four months was only 4.85%, demonstrating excellent adherence. Notably, as part of Hainan Province’s practical livelihood initiative, the “Hainan Province Digital Therapeutic Intervention Project for Children Aged 0–6 with Autism,” the product serves 1,016 children under six years old with ASD across 14 hospitals and three designated institutions of the Disabled Persons’ Federation in eight cities/counties of Hainan. In this project, the monthly attrition rate reached as low as 4.21%, the monthly completion rate stood at 130.69%, and the average daily usage time per patient was 33.16 minutes, yielding significant benefits.

This case innovatively leverages cutting-edge AI technologies, including natural language processing and user recommendation algorithms. Based on a fully independent intellectual property portfolio and an empirically validated online assessment and intervention system, it utilizes nearly 390,000 data points on developmental milestones of children with special needs, over 90 million offline rehabilitation records accumulated by empirical centers, as well as datasets comprising intervention command texts and speech, interaction transcripts, behavioral videos, and materials related to projects, levels, and scenarios. A knowledge graph for autism cognitive ability and social skills intervention programs was constructed. By integrating patient user profiles and behavioral characteristics, models were trained to recommend intervention programs via the shortest path. The system dynamically generates digital scenarios matched to these interventions and corresponding digital items aligned with the contexts. Furthermore, it synthesizes instructional and interactive speech based on emotional features extracted from patients' voice feedback, thereby delivering cognitive interventions and immersive, life-like social skills training. This approach enhances compliance and improves the overall efficacy of the intervention.

Case Name:Shu Kang Shi

Selected Organizations:Beijing Yiyue Technology Co., Ltd.

Collaborating Organizations:Peking University Third Hospital

Application Subfields/Departments/Diseases:Orthopedics, Sports Medicine, Rehabilitation

Annual Innovation Achievements and Outcomes:

Shu Kang Shi builds a full-process rehabilitation ecosystem, spanning multiple scenarios including hospital outpatient clinics, inpatient treatment wards, and home-based rehabilitation. Through four core modules—assessment, prescription, AI training, and remote rehabilitation—it achieves seamless integration between in-hospital and out-of-hospital care. Patients can choose to train either within or outside the hospital, receiving guidance from both physicians and AI; physicians can also leverage AI decision trees to remotely adjust rehabilitation plans.

Shukangshi has developed a multimodal radar and 3D vision fusion sensor that provides high-precision patient assessment and training guidance. Its accuracy and convenience surpass those of traditional sensor products, offering comprehensive rehabilitation solutions. Shukangshi helps bridge the gap in rehabilitation resources, addressing shortages of rehabilitation personnel and hospital beds, improving the standard of rehabilitation care, and enabling primary healthcare institutions to deliver rehabilitation treatments comparable to those at tertiary Grade A hospitals. Personalized treatment plans and intelligent tools make remote rehabilitation possible. The AI-enabled remote rehabilitation model improves rehabilitation conditions for patients in remote areas and reduces the need for frequent hospital visits. It shortens outpatient prescription time, optimizes inpatient rehabilitation plans, and enhances overall rehabilitation service capabilities. Shukangshi has been validated in nearly 5,000 cases at Peking University Third Hospital and is currently deployed in over 100 hospitals across China, having received multiple software copyrights, patents, and awards.

Case Name:Digital Therapeutics-Based Inhalation Therapy Management Solution

Selected Organizations:Chengyi Jiaren Technology (Tianjin) Co., Ltd.

Application Subfields/Departments/Diseases:Chronic Diseases, Respiratory Medicine, COPD, Asthma

Annual Innovation Achievements and Outcomes:

Digital Therapy-Based Inhalation Treatment Management SolutionOfficially launched in 2022, this solution follows the GOLD-recommended pathway of “treatment monitoring – review and assessment – treatment adjustment.” Driven by software programs, it enables physicians to comprehensively manage patients’ inhalation medication processes both in-hospital and out-of-hospital. Focusing on key technical aspects such as inspiratory capacity assessment/training, inhalation technique evaluation/training, and adherence management for inhalation therapy, the solution innovatively applies a digital therapeutic system. It integrates inhalation resistance simulation devices, IoT technology, large language AI models, and micro-airflow sensing smart hardware to enhance the efficacy of inhalation treatment, significantly improve patients’ quality of life, and reduce the frequency of acute exacerbations. As an effective tool for managing patients with chronic respiratory diseases such as COPD and asthma, it is currently the only solution that truly enables home-based medication management for patients with chronic respiratory conditions (predominantly the elderly) without relying on smartphones.

Digital Therapy-Based Inhalation Treatment Management Solution: The current specific product has obtained the only medical device registration certificate for digital therapeutics in inhalation treatment globally. The scope of application specified in the registration certificate clearly states that it is used to "assist clinicians in analyzing patients' respiratory capacity, helping doctors guide patients in selecting appropriate inhalation drug devices and medications; collect and analyze respiratory data in real-time while patients are inhaling medication, enabling healthcare professionals to monitor patients' respiratory status and capacity in real-time." Currently, it is being clinically used at leading national or regional hospitals such as China-Japan Friendship Hospital, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, West China Hospital of Sichuan University, Second Xiangya Hospital of Central South University, and Henan Provincial People's Hospital.

Case Name:Boshi Zeus Smart Minimally Invasive Surgical Platform

Selected Institutions:Guangzhou Baishi Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Minimally Invasive Specialty

Annual Innovation Performance and Achievements:

The “Zeus” Intelligent Minimally Invasive Surgical Platform, independently developed by Baishi Medical, comprises several subsystems: digital twin-based 3D reconstruction and segmentation, surgical planning, real-time multimodal fusion of imaging and optical holography, 3D visualization with real-time positioning and navigation, and digitally assisted instrument therapy. Guided by the core principles of “digitalization, precision, and standardization,” Baishi Zeus is building a new-generation innovative ecosystem for minimally invasive treatment. It empowers the minimally invasive therapy industry and various clinical subspecialties, enhancing the efficiency and overall effectiveness of medical resource utilization. By promoting equitable and high-quality healthcare services, it makes surgical treatments more accessible, efficient, and safer.

Taking the i Locate Spine minimally invasive spine surgery system, part of the Baishi Zeus Smart Minimally Invasive Surgery Platform, as an example, this system addresses critical pain points in minimally invasive spine procedures—such as prolonged time required to establish surgical access channels, high radiation exposure, elevated risk levels, and intraoperative disorientation regarding instrument positioning and anatomical identification—which often leave physicians unable or hesitant to perform these surgeries. It provides a digital solution that assists surgeons in performing procedures through digital visualization without altering clinical workflows. This approach significantly reduces radiation exposure, enhances surgical efficiency, facilitates the widespread adoption of this technique, and lowers the learning curve for physicians. Consequently, it effectively promotes the decentralization of medical resources, benefiting both doctors and patients.

Case Name:Haizheng Cloud - Digital Medical Supervision and Service Platform

Selected Institutions:Haihu Health (Shandong) Group Co., Ltd.

Application Subfields/Departments/Diseases:Regulation of Internet Hospitals, Digital Therapeutics, and Internet-Plus Nursing Services

Annual Innovation Achievements and Results:

Haizheng Cloud – Digital Healthcare Regulatory Service PlatformTo address inconsistencies in master data—such as hospital medications, laboratory tests, and examinations—as well as the diversity of medical terminology, we have employed natural language processing (NLP) and medical knowledge graph technologies to achieve data standardization. This approach not only resolves the issue of multiple codes for a single item, thereby enhancing the accuracy of statistical data, but also provides standardized medical terminology for data analysis. The platform is at the forefront among internet healthcare regulatory platforms across China’s provinces. It was recognized as an Industry Excellent System in 2023. Currently, its system and operational model are being replicated in regions such as Jiangxi and Yinchuan. The platform already supports the daily regulatory oversight of more than 400 internet hospitals throughout Shandong Province, playing a positive role in promoting the development and regulation of local internet healthcare.The Shandong Provincial Internet Healthcare Regulatory Service Platform was custom-developed in strict compliance with national regulatory policy requirements, based on a thorough interpretation and breakdown of China’s national internet healthcare regulatory policies.

Case Name:Jingyi Qianxun Large Language Model

Selected Organizations:JD Health (6618.HK)

Application Subfields/Departments/Diseases:Medical Imaging Analysis, Clinical Text Processing, Multimodal Data Processing

Annual Innovation Performance and Achievements:

Case Name:Intelligent Ultrasound Screening Device for Cardiovascular and Cerebrovascular Diseases

Selected Institutions:LingShu Medical Technology (Suzhou) Co., Ltd.

Partner Organizations:Institute of Automation, Chinese Academy of Sciences

Application Subfields/Departments/Disease Types:Primary Care, Cardiology Department, Health Examination Center, Elderly Care Nursing Home

Annual Innovation Achievements and Outcomes:

The Intelligent Ultrasound Screening System for Cardiovascular and Cerebrovascular Diseases integrates four core modules: autonomous scanning, 3D reconstruction, assisted diagnosis, and intelligent services, significantly enhancing screening efficiency and service capabilities. Its portable desktop design, combined with a SCARA-like architecture, enables precise probe movement and adjustment. The deployment of a cloud-edge-end collaborative service platform ensures real-time analysis of ultrasound images and efficient resource allocation. Cloud-based diagnostic algorithms and reporting modules support case management and statistical analysis. These innovations reduce costs and substantially improve the supply capacity and examination efficiency of ultrasound services.

Cardiovascular and cerebrovascular diseases have become the leading cause of death among residents in China. Faced with a large population at high risk, intelligent ultrasound screening devices for cardiovascular and cerebrovascular conditions can significantly improve screening efficiency. With one-click data acquisition, these devices leverage artificial intelligence to empower stroke and cardiovascular disease screening, and have already been deployed in healthcare institutions across multiple provinces in China. In 2023, as part of the Yangtze River Delta Medical-Prevention Integration Project in Tongling City, Anhui Province, primary healthcare workers used intelligent cardiovascular and cerebrovascular ultrasound screening devices to conduct stroke ultrasound screenings for 20,000 local residents, substantially enhancing the diagnostic capability and quality of primary healthcare services.

To date, this initiative has expanded to more than ten provinces and 48 cities across China, achieving widespread adoption in medical institutions at all levels and across diverse clinical settings. It has benefited tens of thousands of residents in primary care communities, effectively advancing the in-depth implementation of cardiovascular and cerebrovascular disease screening, while significantly improving the accessibility and efficiency of ultrasound examinations.

Case Name:Digital Respiratory Chronic Disease Management System

Selected Institutions:Shenzhen Rongxin Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Respiratory and Sleep Health

Annual Innovation Performance and Achievements:

The remote digital service model for chronic respiratory diseases achieves efficient screening, remote services, and personalized treatment for Obstructive Sleep Apnea Syndrome (OSAS) by introducing the ResAsist digital chronic respiratory disease management system. Leveraging big data, the Internet of Things (IoT), and artificial intelligence technologies, the platform significantly enhances medical service efficiency, enabling real-time upload and remote digital management of patient data. Multi-terminal access (smart devices, mini-programs, apps, and web interfaces) makes medical services more convenient, truly embodying the “patient-centered” service philosophy. This allows patients to enjoy comprehensive, personalized respiratory and sleep management services, significantly improving both patient experience and treatment outcomes.

ResAsist Digital Respiratory Chronic Disease Management System delivers an unprecedented digital service experience by deeply integrating real-world patient data, artificial intelligence, and smart sleep apnea devices. Compared with other similar solutions, its key advantages lie in the deep integration of massive datasets with intelligent devices, broad regional applicability, significant industry potential for addressing obstructive sleep apnea syndrome (OSAS), and strong reproducibility and scalability in healthcare management.

Case Name:Intracardiac Echocardiography Imaging System

Selected Institutions:Shenzhen Saihe Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Cardiovascular

Annual Innovation Achievements and Results:

Intracardiac Echocardiography (ICE) ingeniously combines phased-array ultrasound imaging with cardiac catheterization, providing an innovative ultrasound imaging solution for percutaneous vascular interventional procedures. Saihe Medical’s ICE system consists of DynaSight^®It consists of a single-use intracardiac echocardiography (ICE) catheter and the UDG3900 series portable ultrasound diagnostic system. By continuously transmitting and receiving ultrasound signals via a miniature phased-array transducer, it achieves real-time, high-quality imaging of intracardiac anatomical structures, serving as a critical imaging modality in interventional cardiology procedures.

Saihe Medical’s independently developed domestic intracardiac echocardiography (ICE) system has received high recognition from experts in the DISTINCT clinical trial. Its overall performance, including catheter maneuverability and image quality, not only matches that of imported counterparts but even surpasses them in certain aspects. Notably, innovative technologies have enabled the system to achieve greater detection depth, making it suitable not only for routine cardiac interventional procedures but also for optimizing the workflow of ICE-guided left atrial appendage closure surgeries, significantly improving procedural efficiency and reducing complications. As the first domestically produced ICE system (comprising both catheter and console) to enter the innovation fast-track channel and receive regulatory approval in China, Saihe Medical’s independently developed ICE system marks the rise of domestic intracardiac ultrasound technology.

Case Name:AI-Based Medical Imaging Enhancement Product: SupMR

Selected Institutions:Shenzhen Zhitou Medical Technology Development (Shanghai) Co., Ltd.

Application Subfields/Departments/Diseases:Medical Imaging

Annual Innovation Achievements and Results:

SupMR leverages deep learning technology to accelerate MRI examinations and enhance image quality and resolution. By employing generative AI techniques, it can speed up the MRI imaging process by 2–4 times or reduce contrast agent usage by 90%, while delivering superior image quality and diagnostic efficacy compared to pre-acceleration standards.

Leveraging proprietary deep learning and generative AI model algorithms, SupMR enables healthcare institutions to examine more patients in less time while reducing radiation doses, thereby eliminating patient wait times. Furthermore, SupMR achieves seamless compatibility with various OEM scanners and PACS systems. This means that SupMR can be deployed as a SaaS solution without disrupting the daily workflows of radiologists. It eliminates the need for costly hardware purchases, allowing for convenient and rapid deployment within hospitals through software alone, thus optimizing all clinical equipment.

Currently, DeepWise AI’s SupMR has been implemented in clinical settings across markets in China, the United States, and Europe. It has been deployed in nearly 600 healthcare institutions and imaging centers worldwide, establishing partnerships with more than a dozen leading U.S. medical schools, hospitals, and third-party imaging centers, including Stanford University School of Medicine, UCSF, MD Anderson Cancer Center, and Mayo Clinic.Secondly, DeepWisdom AI has also partnered with leading domestic and international medical device manufacturers, including Siemens Healthineers, NanoVision Imaging, and Rigaku, to develop AI-enhanced platforms for their equipment, thereby empowering these devices to achieve superior image quality.In addition, DeepWise Medical has signed agreements with pharmaceutical companies such as Bracco and Bayer. Through close collaboration with globally renowned contrast media manufacturers, it drives the acceleration and optimization of contrast agent R&D, helping pharmaceutical companies achieve intelligent upgrades to their product portfolios and deliver safer, more effective contrast-enhanced medical imaging outcomes.

Case Name:Myopia Risk Factor Monitor

Selected Organizations:12mm Health Technology (Hainan) Co., Ltd.

Partner Organizations:Hainan Eye Hospital

Application Subfields/Departments/Diseases:Adolescent Myopia Prevention and Control

Annual Innovation Achievements and Outcomes:

Case Name:ShukunGPT Empowers the Full Lifecycle of Healthcare

Selected Institutions:Shukun Technology Co., Ltd.

Application Subfields/Departments/Diseases:AI Healthcare

Annual Innovation Achievements and Results:

ShukunGPT, Shukun Technology’s self-developed multimodal large medical model, leverages the company’s top-tier team integrating medicine and engineering along with its original innovation capabilities. Trained efficiently on a high-quality medical data ecosystem, it features cross-modal and interdisciplinary capabilities, with an intelligence level comparable to that of mid-to-senior-level physicians. ShukunGPT assists doctors in efficiently completing diagnostic and treatment tasks, covering the entire patient lifecycle and full-course disease management, thereby comprehensively empowering healthcare and the broader health industry while leading new industrial paradigms. In the task of “large model-driven precise disease diagnosis,” it achieves a single-disease diagnostic accuracy of 98%, a multi-comorbidity diagnostic accuracy of 80%, and doubles diagnostic efficiency.

ShukunGPT was awarded the first prize in the Beijing Industry Large Model Innovation Application Competition (the only one in the medical field) at the Zhongguancun Forum. It ranked first on the CMB, the world’s largest Chinese medical evaluation benchmark, with a state-of-the-art (SOTA) score, and its performance on medical licensing examinations far surpassed that of large models developed by international tech giants. Leveraging proprietary AI technologies and the integration of medicine and engineering, Shukun Technology is poised to address the scarcity of high-quality medical resources. By drawing on its experience in transforming radiology departments—outperforming international tech giants—and its capabilities in medical AI research and development, Shukun aims to expand AI applications from radiology to all clinical departments, extending empowerment from within hospitals to outside settings, thereby completing a closed loop for healthcare management.

Case Name:66Brain Digital Therapeutics for Cognitive Impairment

Selected Institutions:Zhejiang Naodong Jiguang Medical Technology Co., Ltd.

Application Subfields/Departments/Disease Types:Cognitive Impairment

Annual Innovation Achievements and Outcomes:

Liu Liu Nao’s digital therapeutic for cognitive impairment focuses on providing comprehensive health management services to patients with cognitive disorders. This case ingeniously integrates brain science, medicine, and artificial intelligence technologies. Through an internet-based digital therapeutic platform, it achieves comprehensive screening, precise assessment, effective rehabilitation, and continuous monitoring of cognitive impairment. Its application in renowned institutions such as Xuanwu Hospital of Capital Medical University and Beijing Anzhen Hospital fully demonstrates its significant efficacy and substantial potential for widespread adoption in the medical field.

The innovation of this case lies in the development of cognitive function assessment tools tailored to the characteristics of the local population, thereby enhancing the relevance and accuracy of assessments. By leveraging big data and artificial intelligence technologies, intelligent digital therapeutics enable personalized cognitive function assessment and training programs, significantly improving the precision of rehabilitation training and patient experience. Furthermore, the case provides end-to-end services ranging from health monitoring and physical examinations to disease management, establishing a three-tier chronic disease management system linking hospitals, communities, and households. Through collaborations with multiple medical institutions, research achievements are rapidly translated into clinical applications, promoting the standardization and normalization of diagnosis and treatment for cognitive disorders. Meanwhile, a specialized talent training system for cognitive disorders and a direct data reporting system have been established, improving both the efficiency of medical services and the accuracy of research data.